Roche, Blueprint raise pressure on Lilly with new Gavreto approvalThe FDA has cleared Roche and Blueprint Medicine’s Gavreto for a new use in RET-mutated thyroid cancer, putting Share XRoche, Blueprint raise pressure on Lilly with new Gavreto approvalhttps://pharmaphorum.com/news/roche-blueprint-raise-pressure-on-lilly-with-new-gavreto-approval/
